Lisata Therapeutics, Inc. (LSTA)

Market Cap	20.31M
Revenue (ttm)	1.07M
Net Income (ttm)	-18.92M
Shares Out	8.76M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,802
Open	2.310
Previous Close	2.350
Day's Range	2.263 - 2.461
52-Week Range	1.870 - 4.200
Beta	0.94
Analysts	Strong Buy
Price Target	23.50 (+912.93%)
Earnings Date	Aug 7, 2025

About LSTA

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is hea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1980
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: LSTA
• Website: https://www.lisata.com

Analyst Summary

According to 2 analysts, the average rating for LSTA stock is "Strong Buy." The 12-month stock price target is $23.5, which is an increase of 912.93% from the latest price.

Price Target

$23.5

(912.93% upside)

Analyst Consensus: Strong Buy